Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115


Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.

Aymonnier K, Kawecki C, Venisse L, Boulaftali Y, Christophe OD, Lenting PJ, Arocas V, de Raucourt E, Denis CV, Bouton MC.

Blood. 2019 Aug 5. pii: blood.2019000281. doi: 10.1182/blood.2019000281. [Epub ahead of print]


Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]


Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.

Dupont A, Soukaseum C, Cheptou M, Adam F, Nipoti T, Lourenco-Rodrigues MD, Legendre P, Proulle V, Rauch A, Kawecki C, Bryckaert M, Rosa JP, Paris C, Ternisien C, Boisseau P, Goudemand J, Borgel D, Lasne D, Maurice P, Lenting PJ, Denis CV, Susen S, Kauskot A.

Haematologica. 2019 Feb 28. pii: haematol.2018.206250. doi: 10.3324/haematol.2018.206250. [Epub ahead of print]


Platelet Functions are Decreased in Obesity and Restored after Weight Loss: Evidence for a Role of the SERCA3-Dependent ADP Secretion Pathway.

Elaïb Z, Lopez JJ, Coupaye M, Zuber K, Becker Y, Kondratieff A, Repérant C, Pépin M, Salomon L, Teillet F, Msika S, Denis CV, de Prost D, Rosa JP, Bobe R, Stépanian A.

Thromb Haemost. 2019 Mar;119(3):384-396. doi: 10.1055/s-0038-1677033. Epub 2019 Jan 16.


Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity.

Donada A, Balayn N, Sliwa D, Lordier L, Ceglia V, Baschieri F, Goizet C, Favier R, Tosca L, Tachdjian G, Denis CV, Plo I, Vainchenker W, Debili N, Rosa JP, Bryckaert M, Raslova H.

Blood. 2019 Apr 18;133(16):1778-1788. doi: 10.1182/blood-2018-07-861427. Epub 2019 Jan 2.


The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction.

Schneppenheim R, Hellermann N, Brehm MA, Klemm U, Obser T, Huck V, Schneider SW, Denis CV, Tischer A, Auton M, März W, Xu ER, Wilmanns M, Zotz RB.

Blood. 2019 Jan 24;133(4):356-365. doi: 10.1182/blood-2018-04-843425. Epub 2018 Oct 26.


Impact of PI3Kα (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis.

Laurent PA, Hechler B, Solinhac R, Ragab A, Cabou C, Anquetil T, Severin S, Denis CV, Mangin PH, Vanhaesebroeck B, Payrastre B, Gratacap MP.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2041-2053. doi: 10.1161/ATVBAHA.118.311410.


Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor.

Xu ER, von Bülow S, Chen PC, Lenting PJ, Kolšek K, Aponte-Santamaría C, Simon B, Foot J, Obser T, Schneppenheim R, Gräter F, Denis CV, Wilmanns M, Hennig J.

Blood. 2019 Jan 24;133(4):366-376. doi: 10.1182/blood-2018-04-843615. Epub 2018 Oct 10.


A mutation of the human EPHB2 gene leads to a major platelet functional defect.

Berrou E, Soukaseum C, Favier R, Adam F, Elaib Z, Kauskot A, Bordet JC, Ballerini P, Loyau S, Feng M, Dias K, Muheidli A, Girault S, Nurden AT, Turro E, Ouwehand WH, Denis CV, Jandrot-Perrus M, Rosa JP, Nurden P, Bryckaert M.

Blood. 2018 Nov 8;132(19):2067-2077. doi: 10.1182/blood-2018-04-845644. Epub 2018 Sep 13.


A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation.

Kauskot A, Pascreau T, Adam F, Bruneel A, Reperant C, Lourenco-Rodrigues MD, Rosa JP, Petermann R, Maurey H, Auditeau C, Lasne D, Denis CV, Bryckaert M, de Lonlay P, Lavenu-Bombled C, Melki J, Borgel D.

Haematologica. 2018 Dec;103(12):e613-e617. doi: 10.3324/haematol.2018.198028. Epub 2018 Aug 16. No abstract available.


Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure.

Popovic B, Zannad F, Louis H, Clerc-Urmès I, Lakomy C, Gibot S, Denis CV, Lacolley P, Regnault V.

Int J Cardiol. 2019 Jan 1;274:195-201. doi: 10.1016/j.ijcard.2018.07.130. Epub 2018 Jul 25.


A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

Muczynski V, Casari C, Moreau F, Aymé G, Kawecki C, Legendre P, Proulle V, Christophe OD, Denis CV, Lenting PJ.

Blood. 2018 Sep 13;132(11):1193-1197. doi: 10.1182/blood-2018-01-829523. Epub 2018 Jul 31.


Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.


Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Casari C, Paul DS, Susen S, Lavenu-Bombled C, Harroche A, Piatt R, Poe KO, Lee RH, Bryckaert M, Christophe OD, Lenting PJ, Denis CV, Bergmeier W.

Blood Adv. 2018 Jun 26;2(12):1417-1428. doi: 10.1182/bloodadvances.2017014290.


VWF clearance: it's glycomplicated.

Denis CV, Lenting PJ.

Blood. 2018 Feb 22;131(8):842-843. doi: 10.1182/blood-2018-01-824904. No abstract available.


The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent.

Rayes J, Jadoui S, Lax S, Gros A, Wichaiyo S, Ollivier V, Denis CV, Ware J, Nieswandt B, Jandrot-Perrus M, Watson SP, Ho-Tin-Noé B.

Haematologica. 2018 Jun;103(6):e256-e258. doi: 10.3324/haematol.2017.182162. Epub 2018 Feb 1. No abstract available.


Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

Wohner N, Muczynski V, Mohamadi A, Legendre P, Proulle V, Aymé G, Christophe OD, Lenting PJ, Denis CV, Casari C.

Haematologica. 2018 Apr;103(4):728-737. doi: 10.3324/haematol.2017.175216. Epub 2018 Jan 11.


Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Dec 7;130(23):2463-2468. doi: 10.1182/blood-2017-08-801662. Epub 2017 Oct 17. Review.


Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

Muczynski V, Christophe OD, Denis CV, Lenting PJ.

Semin Thromb Hemost. 2017 Sep;43(6):581-590. doi: 10.1055/s-0037-1604053. Epub 2017 Jul 27. Review. No abstract available.


von Willebrand factor and inflammation.

Kawecki C, Lenting PJ, Denis CV.

J Thromb Haemost. 2017 Jul;15(7):1285-1294. doi: 10.1111/jth.13696. Review.


A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, Christophe OD, Lenting PJ.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1736-1740. doi: 10.1161/ATVBAHA.117.309319. Epub 2017 Jun 22.


Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi.

Martinez de Lizarrondo S, Gakuba C, Herbig BA, Repessé Y, Ali C, Denis CV, Lenting PJ, Touzé E, Diamond SL, Vivien D, Gauberti M.

Circulation. 2017 Aug 15;136(7):646-660. doi: 10.1161/CIRCULATIONAHA.117.027290. Epub 2017 May 9.


Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

Muczynski V, Aymé G, Regnault V, Vasse M, Borgel D, Legendre P, Bazaa A, Harel A, Loubière C, Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Apr 27;129(17):2443-2454. doi: 10.1182/blood-2016-06-724351. Epub 2017 Feb 17.


Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice.

Kirschbaum M, Jenne CN, Veldhuis ZJ, Sjollema KA, Lenting PJ, Giepmans BNG, Porte RJ, Kubes P, Denis CV, Lisman T.

Liver Int. 2017 Nov;37(11):1731-1737. doi: 10.1111/liv.13386. Epub 2017 Mar 5.


Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.

Pepin M, Mezouar S, Pegon J, Muczynski V, Adam F, Bianchini EP, Bazaa A, Proulle V, Rupin A, Paysant J, Panicot-Dubois L, Christophe OD, Dubois C, Lenting PJ, Denis CV.

Sci Rep. 2016 Nov 28;6:37953. doi: 10.1038/srep37953.


Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.

Espitia O, Ternisien C, Agard C, Boisseau P, Denis CV, Fouassier M.

Platelets. 2017 Jul;28(5):518-520. doi: 10.1080/09537104.2016.1246717. Epub 2016 Nov 25.


Network-based analysis of omics data: the LEAN method.

Gwinner F, Boulday G, Vandiedonck C, Arnould M, Cardoso C, Nikolayeva I, Guitart-Pla O, Denis CV, Christophe OD, Beghain J, Tournier-Lasserve E, Schwikowski B.

Bioinformatics. 2017 Mar 1;33(5):701-709. doi: 10.1093/bioinformatics/btw676.


Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura.

Le Besnerais M, Favre J, Denis CV, Mulder P, Martinet J, Nicol L, Levesque H, Veyradier A, Kopić A, Motto DG, Coppo P, Richard V, Benhamou Y.

J Thromb Haemost. 2016 Oct;14(10):1917-1930. doi: 10.1111/jth.13439. Epub 2016 Sep 28.


LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex.

Fazavana JG, Muczynski V, Proulle V, Wohner N, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2016 Dec;14(12):2458-2470. doi: 10.1111/jth.13502. Epub 2016 Oct 25.


LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Aymé G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa JP, Lenting PJ, Bryckaert M, Denis CV, Baruch D.

JCI Insight. 2016 Oct 6;1(16):e88643. doi: 10.1172/jci.insight.88643.


Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Obser T, Ledford-Kraemer M, Oyen F, Brehm MA, Denis CV, Marschalek R, Montgomery RR, Sadler JE, Schneppenheim S, Budde U, Schneppenheim R.

J Thromb Haemost. 2016 Sep;14(9):1725-35. doi: 10.1111/jth.13398. Epub 2016 Aug 20.


Antibody-Based Protection of von Willebrand Factor Degradation.

Lenting PJ, Denis CV, Susen S, van Belle E.

JACC Heart Fail. 2016 Jun;4(6):518. doi: 10.1016/j.jchf.2015.12.018. No abstract available.


Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis.

Abdelmagid N, Bereczky-Veress B, Atanur S, Musilová A, Zídek V, Saba L, Warnecke A, Khademi M, Studahl M, Aurelius E, Hjalmarsson A, Garcia-Diaz A, Denis CV, Bergström T, Sköldenberg B, Kockum I, Aitman T, Hübner N, Olsson T, Pravenec M, Diez M.

PLoS One. 2016 May 25;11(5):e0155832. doi: 10.1371/journal.pone.0155832. eCollection 2016.


A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Adam F, Casari C, Prévost N, Kauskot A, Loubière C, Legendre P, Repérant C, Baruch D, Rosa JP, Bryckaert M, de Groot PG, Christophe OD, Lenting PJ, Denis CV.

Sci Rep. 2016 May 23;6:26306. doi: 10.1038/srep26306.


A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.


Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.

Berrou E, Kauskot A, Adam F, Harel A, Legendre P, Lavenu Bombled C, Rothschild C, Prevost N, Christophe OD, Lenting PJ, Denis CV, Rosa JP, Bryckaert M.

PLoS One. 2015 Dec 8;10(12):e0143896. doi: 10.1371/journal.pone.0143896. eCollection 2015.


Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X.

Muczynski V, Bazaa A, Loubière C, Harel A, Cherel G, Denis CV, Lenting PJ, Christophe OD.

Blood. 2016 Feb 11;127(6):778-86. doi: 10.1182/blood-2015-05-647032. Epub 2015 Nov 25.


Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice.

Decouture B, Dreano E, Belleville-Rolland T, Kuci O, Dizier B, Bazaa A, Coqueran B, Lompre AM, Denis CV, Hulot JS, Bachelot-Loza C, Gaussem P.

Blood. 2015 Oct 8;126(15):1823-30. doi: 10.1182/blood-2015-02-631044. Epub 2015 Aug 27.


Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.

Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2015 May;13(5):815-20. doi: 10.1111/jth.12885. Epub 2015 Mar 31.


von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.

Lenting PJ, Christophe OD, Denis CV.

Blood. 2015 Mar 26;125(13):2019-28. doi: 10.1182/blood-2014-06-528406. Epub 2015 Feb 23. Review.


Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis.

Strassel C, Kubovcakova L, Mangin PH, Ravanat C, Freund M, Skoda RC, Denis CV, Dupuis A, Herbrecht R, Gachet C, Lanza F.

Thromb Haemost. 2015 Feb;113(2):414-25. doi: 10.1160/TH14-08-0667. Epub 2014 Oct 9.


Of von Willebrand factor and platelets.

Bryckaert M, Rosa JP, Denis CV, Lenting PJ.

Cell Mol Life Sci. 2015 Jan;72(2):307-26. doi: 10.1007/s00018-014-1743-8. Epub 2014 Oct 9. Review.


Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.

Thromb Haemost. 2014 Nov;112(5):1014-23. doi: 10.1160/TH14-02-0148. Epub 2014 Jul 17.


Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Lamrani L, Lacout C, Ollivier V, Denis CV, Gardiner E, Ho Tin Noe B, Vainchenker W, Villeval JL, Jandrot-Perrus M.

Blood. 2014 Aug 14;124(7):1136-45. doi: 10.1182/blood-2013-10-530832. Epub 2014 Jun 20.


Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

Morioka Y, Casari C, Wohner N, Cho S, Kurata S, Kitano A, Christophe OD, Lenting PJ, Li R, Denis CV, Prévost N.

Blood. 2014 May 22;123(21):3344-53. doi: 10.1182/blood-2013-10-531392. Epub 2014 Apr 8.


Neutrophils mediate edema formation but not mechanical allodynia during zymosan-induced inflammation.

Suo J, Linke B, Meyer dos Santos S, Pierre S, Stegner D, Zhang DD, Denis CV, Geisslinger G, Nieswandt B, Scholich K.

J Leukoc Biol. 2014 Jul;96(1):133-42. doi: 10.1189/jlb.3A1213-628R. Epub 2014 Feb 20.


GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice.

Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, Guillou S, Denis CV, Maubert E, Orset C, Vivien D.

Blood. 2014 May 22;123(21):3354-63. doi: 10.1182/blood-2013-12-543074. Epub 2014 Feb 19.


Platelet von Willebrand factor: sweet resistance.

Lenting PJ, Denis CV.

Blood. 2013 Dec 12;122(25):4006-7. doi: 10.1182/blood-2013-10-533174.


von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

Casari C, Berrou E, Lebret M, Adam F, Kauskot A, Bobe R, Desconclois C, Fressinaud E, Christophe OD, Lenting PJ, Rosa JP, Denis CV, Bryckaert M.

J Clin Invest. 2013 Dec;123(12):5071-81. doi: 10.1172/JCI69458. Epub 2013 Nov 25.


Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.

Casari C, Du V, Wu YP, Kauskot A, de Groot PG, Christophe OD, Denis CV, de Laat B, Lenting PJ.

Blood. 2013 Oct 17;122(16):2893-902. doi: 10.1182/blood-2013-03-493312. Epub 2013 Aug 14.

Supplemental Content

Loading ...
Support Center